<SEC-DOCUMENT>0001437749-24-009476.txt : 20240327
<SEC-HEADER>0001437749-24-009476.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240326202830
ACCESSION NUMBER:		0001437749-24-009476
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240326
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZEVRA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001434647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205894398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36913
		FILM NUMBER:		24785462

	BUSINESS ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747
		BUSINESS PHONE:		(321) 939-3416

	MAIL ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM, INC
		DATE OF NAME CHANGE:	20130530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM INC
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zvra20240326_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:zvra="http://www.zvra.com/20240326"><head>
	<title>zvra20240326_8k.htm</title>


<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-377">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-378">0001434647</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="zvra-20240326.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001434647</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-03-26</xbrli:startDate>
<xbrli:endDate>2024-03-26</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>
<!-- Generated by ThunderDome Portal - 3/27/2024 12:19:03 AM -->
<hr style="margin: 3pt 0px; border: currentColor; border-image: none; width: 100%; height: 3px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/>
<hr style="margin: 0px 0px 3pt; border: currentColor; border-image: none; width: 100%; height: 1px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/>
<div style="margin: 0pt; text-align: center; color: rgb(0, 0, 0); text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, Serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&#160;</div>

<div style="margin: 0pt; text-align: center; color: rgb(0, 0, 0); text-indent: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 18pt; background-color: rgb(255, 255, 255);"><b>UNITED STATES</b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>WASHINGTON, D.C. 20549 </b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt;"><b>FORM <ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-22"><b>8-K</b></ix:nonNumeric></b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"><span style="font-size:10pt;"><b>CURRENT REPORT </b></span></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-37"><b>March 26, 2024</b></ix:nonNumeric></b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 24pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-43"><b>Zevra Therapeutics, Inc.</b></ix:nonNumeric></div>

<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Exact Name of Registrant as Specified in Its Charter) </b></div>

<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="TBL1" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-56"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-60"><b>001-36913</b></ix:nonNumeric></div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-64"><b>20-5894398</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
			<td style="width: 33%; vertical-align: top; padding: 0px; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Commission&#160;File </b></div>
			</td>
			<td style="width: 33%; vertical-align: top; padding: 0px; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(I.R.S. Employer Identification </b></div>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(State or Other Jurisdiction of Incorporation)</b></div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><b>Number)</b></td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><b>No.)</b></td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-88"><strong>1180 Celebration Boulevard</strong><strong>, <strong><strong>Suite 103</strong></strong></strong></ix:nonNumeric><strong>,</strong></td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-98"><strong><strong><strong><strong>Celebration</strong></strong></strong></strong></ix:nonNumeric><strong>, <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressStateOrProvince" id="ixv-104"><strong><strong><strong><strong><strong><strong>FL</strong></strong></strong></strong></strong></strong></ix:nonNumeric></strong></td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-113"><b>34747</b></ix:nonNumeric></td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;"><b>(Address of Principal Executive Offices)&#160;</b></td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><b>(Zip Code)</b></td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 8pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Registrant&#8217;s Telephone Number, Including Area Code:&#160;(<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-130"><b>321</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-132"><b>939-3416</b></ix:nonNumeric></b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Former Name or Former Address, if Changed Since Last Report)</b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB2" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-388">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB3" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-389">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB4" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-390">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB5" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-391">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#160;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="font-size: 10pt;">
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title of each class</div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: top; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-392">Common Stock</ix:nonNumeric></div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: top; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-393">ZVRA</ix:nonNumeric></div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: middle; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The <ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-394">Nasdaq</ix:nonNumeric> Stock Market LLC</div>

			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Nasdaq Global Select Market)</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;<span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Emerging growth company&#160; &#160;<ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-395">&#9744;</ix:nonNumeric></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a<span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">) of the Exchange Act.&#160; &#160;&#9744;</span></div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>Item 7.01</b>&#160;<b> </b>&#160;<b> </b>&#160;<b> </b>&#160;<b> </b>&#160;<b> Regulation FD Disclosure.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On March 26, 2024, Zevra Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing&#160;top-line data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (IH).&#160;A copy of the press release is attached&#160;as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>Item 8.01.</b>&#160; &#160; &#160; &#160; &#160;&#160;<b>Other Events.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">As noted in Item 7.01 above, on March 26, 2024, the Company announced top-line data from the Phase 2 Clinical Trial of KP1077 for IH. The positive top-line results of the Phase 2 trial support the safety and tolerability of KP1077 as measured by the primary endpoint of the study. The study also successfully fulfilled the objectives of providing key information for the design of a potentially pivotal efficacy trial, and the results of the secondary efficacy endpoints were supportive of initiating a Phase 3 trial of KP1077.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">KP1077 was shown to be well-tolerated at all dose levels evaluated in the trial, including the highest dose of 320 mg daily, regardless of dosing regimen (once or twice daily). The most common adverse events were insomnia, headache, anxiety, nausea, and decreased appetite. Due to its unique pharmacokinetic profile, adverse events were mostly mild in severity despite higher overall exposure levels when compared to both immediate and long-acting methylphenidate products currently used off-label for the treatment of IH.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">Topline results of the Phase 2 study include:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">KP1077 produced clinically meaningful improvement in excessive daytime sleepiness (EDS), as assessed by change from baseline in the Epworth Sleepiness Scale (ESS), that was maintained during both the five-week open-label titration period and throughout the 2-week double-blind withdrawal period for both dosing regimens.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients administered KP1077 showed benefits in change from baseline for the IH Severity Scale (IHSS), Sleep Inertia Visual Analog Scale (SIVAS) and Brain Fog severity Scale (BFS) at the end of the open-label dose titration, and at the end of the double-blind withdrawal period.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 0%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</div>
			</td>
			<td style="vertical-align: middle; width: 99%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -2pt;"><b>Caution Concerning Forward-Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">This Current Report on Form 8-K may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the promise and potential impact of our preclinical or clinical trial data; the design, initiation, timing and results of any clinical trials or readouts; interpretations of trial data outcomes on clinical safety and efficacy; the promise and potential impact of any of our products or product candidates for any specific disease indication or at any dosage; Zevra&#8217;s plans to request an end-of-Phase 2 (EOP2) meeting; the potential launch or commercialization of any of product candidates or products, and our strategic and product development objectives. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the &#8220;Risk Factors&#8221; section of Zevra&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, as updated in Zevra&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and Zevra&#8217;s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this Current Report on Form 8-K.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Item 9.01.</b>&#160; &#160; &#160; &#160; &#160;&#160;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(d)&#160;Exhibits</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 93%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Description</b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_645330.htm" style="-sec-extract:exhibit;">Press Release dated March 26, 2024.</a></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">104</div>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div class="PGNUM" style="width: 100%; text-align: center;">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="width: 100%; text-align: left;">&#160;</div>
</div>

<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="TBL8" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 45.4%; vertical-align: top;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td colspan="2" style="width: 49.6%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Zevra Therapeutics, Inc</b></span><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>.</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: middle;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>

			<div style="font-size: 10pt;">Date: March 26, 2024</div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">By:</div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">/s/ Timothy J. Sangiovanni</div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: middle;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&#160;</b></div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Timothy J. Sangiovanni, CPA</div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&#160;</b></div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Senior Vice President, Corporate Controller</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_645330.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_645330.htm</title>
	<!-- Generated by ThunderDome Portal - 3/26/2024 8:23:42 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: small-caps; margin: 0pt; text-align: right;">&nbsp;</p>

<div style="text-align: center;"><img alt="picture3.jpg" src="picture3.jpg"></div>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>KP1077 for Idiopathic Hypersomnia</b>&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><i>KP1077 demonstrates clinically meaningful benefits for key IH symptoms</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><i>Top-line data provide key information for the design of a Phase 3 study</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Celebration, Fla. </b>&#8211;<b> March 26, 2024</b> (GLOBE NEWSWIRE) &#8211;&nbsp;Zevra Therapeutics, Inc.&nbsp;(NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.&nbsp; The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;Zevra&#8217;s Phase 2 trial evaluating KP1077 as a treatment for IH demonstrated clinically meaningful impact and encouraging outcomes on both clinical safety and efficacy,&#8221; stated Christopher Drake, PhD, FAASM, DBSM, Principal Investigator of the study.&nbsp; &#8220;During the open-label dose titration period, patients showed robust improvements in IH symptom severity, including excessive daytime sleepiness that were maintained during the double-blind withdrawal period. At the end of the study, patients randomized into the KP1077 treatment group also demonstrated improvements in patient reported IH&nbsp;specific outcomes. We look forward to presenting the final results of the Phase&nbsp;2 trial at the upcoming SLEEP 2024 annual meeting.&#8221;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;We&#8217;re thankful to the patients in the Phase 2 clinical trial for their participation in advancing the investigational treatment, KP1077, for IH,&#8221; said Neil McFarlane, Chief Executive Officer of Zevra.&nbsp; &#8220;We believe KP1077 has strong potential to alleviate the immense burden of key IH symptoms, including excessive daytime sleepiness, sleep inertia and brain fog, and could provide a differentiated treatment option for patients underserved by currently available therapies. We would also like to thank our IH-focused patient advocacy group partners and supporters for making this clinical trial possible. Their partnership in raising awareness for this study and supporting trial enrollment has been crucial for its success.&#8221;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">The positive top-line results of the Phase 2 trial support the safety and tolerability of KP1077 as measured by the primary endpoint of the study. The study also successfully fulfilled the objectives of providing key information for the design of a potentially pivotal efficacy trial, and the results of the secondary efficacy endpoints were supportive of initiating a Phase 3 trial of KP1077.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">KP1077 was shown to be well-tolerated at all dose levels evaluated in the trial, including the highest dose of 320 mg daily, regardless of dosing regimen (once or twice daily). The most common adverse events were insomnia, headache, anxiety, nausea, and decreased appetite. Due to its unique pharmacokinetic profile, adverse events were mostly mild in severity despite higher overall exposure levels when compared to both immediate and long-acting methylphenidate products currently used off-label for the treatment of IH.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">Topline results of the Phase 2 study include:</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Calibri, Arial, sans-serif; font-size: 12pt;">

		<tr style="font-family: Calibri, Arial, sans-serif; font-size: 12pt;">
			<td style="width: 40pt; font-family: Calibri, Arial, sans-serif; font-size: 12pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 18pt; font-family: Calibri, Arial, sans-serif; font-size: 12pt;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; font-family: Calibri, Arial, sans-serif; font-size: 12pt;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt; text-align: justify;">KP1077 produced clinically meaningful improvement in excessive daytime sleepiness (EDS), as assessed by change from baseline in the Epworth Sleepiness Scale (ESS), that was maintained during both the five-week open-label titration period and throughout the 2-week double-blind withdrawal period for both dosing regimens.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt; text-align: justify;">Patients administered KP1077 showed benefits in change from baseline for the IH Severity Scale (IHSS), Sleep Inertia Visual Analog Scale (SIVAS) and Brain Fog severity Scale (BFS) at the end of the open-label dose titration, and at the end of the double-blind withdrawal period.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;"><b>About the KP1077 Phase 2 Trial</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">The Phase 2 clinical trial was a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center study that evaluated the safety and efficacy of KP1077 for the treatment of IH.&nbsp;&nbsp; Part 1 of the trial consisted of a five-week open-label dose titration phase during which patients were optimized to one of four doses of KP1077 (80, 160, 240, or 320 mg/day).&nbsp; Part 2 of the trial entailed a two-week randomized, double-blind, withdrawal phase, during which two-thirds of the trial participants continued to receive their optimized dose while the remaining one-third received placebo. Participants were assigned into two evenly divided cohorts.&nbsp; The first cohort received a single daily dose just before bedtime, and the second cohort received half the daily dose shortly after awakening and the second half prior to bedtime. Zevra enrolled 66 adult patients with IH in 24 centers in the U.S into the open-label titration phase of the study and 50 of those patients continued into the double-blind phase.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">The primary endpoint was the safety and tolerability of KP1077.&nbsp; The major secondary efficacy endpoint was the change in Epworth Sleepiness Scale (ESS) total score.&nbsp; Additional secondary endpoints included the IH Severity Scale (IHSS), the Sleep Inertia Visual Analog Scale (SIVAS), and a new scale to assess the symptoms and severity of brain fog.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;"><b>About Idiopathic Hypersomnia (IH)</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">Idiopathic hypersomnia (IH) is a rare sleep disorder characterized by excessive daytime sleepiness (EDS).&nbsp; Patients with IH experience daytime lapses into sleep, or an irrepressible need to sleep that persists even with adequate or prolonged nighttime sleep. Additionally, those with IH have extreme difficulty waking, otherwise known as sleep inertia, severe brain fog, and often fall asleep unintentionally or at inappropriate times. These symptoms of IH often lead to further, even more debilitating problems such as memory lapses, difficulty maintaining focus, and depression.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">It is estimated, based on claims data, that approximately 37,000 patients in the United States are currently diagnosed with IH, although the total patient population may be much larger due to some patients who have not yet been diagnosed, have been misdiagnosed, or are not currently seeking treatment.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>About KP1077</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">KP1077 (serdexmethylphenidate or SDX) is Zevra&#8217;s proprietary prodrug of d-methylphenidate (d-MPH) and its sole active pharmaceutical ingredient (API).&nbsp; KP1077 has been granted Orphan Drug Designation by the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) for the treatment of IH, and the&nbsp;U.S. Drug Enforcement Agency&nbsp;(DEA) has classified SDX, the sole API in KP1077, as a Schedule IV controlled substance based on evidence suggesting SDX has a lower potential for abuse when compared to d-MPH, a Schedule II controlled substance.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;"><b>About Zevra Therapeutics</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">Zevra Therapeutics is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">For more information, please visit&nbsp;www.zevra.com&nbsp;or follow us on&nbsp;X&nbsp;(formerly Twitter) and&nbsp;LinkedIn.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;"><b>Caution Concerning Forward-Looking Statements</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: justify; margin: 0pt;">This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the promise and potential impact of our preclinical or clinical trial data; the design, initiation, timing and results of any clinical trials or readouts; interpretations of trial data outcomes on clinical safety and efficacy; Zevra&#8217;s reports regarding or presentation of trial data, including at conferences, or the timing thereof; the promise and potential impact of any of our products or product candidates for any specific disease indication or at any dosage; Zevra&#8217;s plans to request an end-of-Phase 2 (EOP2) meeting; the potential launch or commercialization of any of product candidates or products, and our strategic and product development objectives, including with respect to becoming a leading, commercially focused rare disease company. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the &#8220;Risk Factors&#8221; section of Zevra&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, as updated in Zevra&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and Zevra&#8217;s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>Zevra Contact</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">Nichol Ochsner<br>
+1 (732) 754-2545<br>
nochsner@zevra.com</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>Russo Partners Contacts</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">Adanna G. Alexander, Ph.D.<br>
+1 (646) 942-5603<br>
adanna.alexander@russopartnersllc.com</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">Ignacio Guerrero-Ros, Ph.D.<br>
+1 (646) 942-5604<br>
ignacio.guerrero-ros@russopartnersllc.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zvra-20240326.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/27/2024 12:28:13 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:zvra="http://www.zvra.com/20240326" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.zvra.com/20240326">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20240326_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20240326_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20240326_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.zvra.com/20240326/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="zvra_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>zvra-20240326_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/27/2024 12:28:13 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.zvra.com/20240326/role/statement-document-and-entity-information" xlink:href="zvra-20240326.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.zvra.com/20240326/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>zvra-20240326_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/27/2024 12:28:13 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>zvra-20240326_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/27/2024 12:28:14 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.zvra.com/20240326/role/statement-document-and-entity-information" xlink:href="zvra-20240326.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.zvra.com/20240326/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>picture3.jpg
<TEXT>
begin 644 picture3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M(\D0\M$C"A/-C+O(BA@2 >7(_:2P>)G3MS>[J[::N^KTV'+<_5$?\&Y2E?\
MD[3]JCZ_\)<W^%?6GQ)_9$O-:_X)\:E\&-+\8>+I=5C\(_V%IOB>359(-9:[
MBA M[M[F,AA+YJ([,#SSG()!^*?^&FO^"KRKQ^SS\ O_  +C_P#E]7Z,?L_Z
MKXSU_P"!_A&]^(FF:=HOCR\TFVE\0V&G-FTLKYHU,\41\R4%%<D ^8_ ^\>M
M>7CJV*]V56HI6=U9Q?Y#1^&__!NA^WEXZ\)?\%![SX9_$3QCXNURW^(6G3Z4
MMMX@UFZU!K'5[$R3*J?:&=HR46]C95V[CMW<HH'[F?';XR:-^SO\%?%7CSQ%
M(\>A^#]*N=7O?+QYCQPQM(40,0"[8"J"1EF [U_/'_P6M^$VI?\ !.__ (+$
M7'Q \+PM:)K6K6/Q1T/'W&O!="6[C(!Y5[R&9G4D;EN2#\K"OO'_ (.&_P!M
M9OB;_P $]OA3X'^&;-JFN?M-W^G2Z;9Q2 /=:<5BG2/<&PIENYK"$[OE*/-R
M-N:]?-,##%8BA7I:1JI7\K;_ '+\A)V.K_X-J-,^(GQ9^ OQ"^.GQ.\3>)-<
MUKXJ>)K@:;9WNK7-SI^GVMN[&9K2"61E@1KR6YC5% Q%:PX)!K\Y?V;O#7C?
M]N3_ (+#>,OA+JWQI^,OA?0=4\9>+@D^B>+;R.2S2UO+QXHXT>0QJG[M5P%X
M7ICBOZ"/V5/V?-+_ &4OV<_!'PWT5_.T_P %Z/;Z4D^S8;MHT DF*Y.#))O<
MC. 7(%?SD_LN_M;>'_V&?^"U'C'XF^*[#6-0\.Z'X]\7V]\FEQ++<Q+<7][
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M6'L?CK]H.]_X)2?\$DF\7_$&T6^UOX<Z)%I_V1+CSXKN]DN5M+./S<\0M)+
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M91F21I4S"!%@.Q8"OH;_ (*U:5)K7_!+_P#:%M[>%9KJ;X<:_%"IV@EFL)@
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<#&4;55BBBO4Q%2%&7)[.,M$[N]]=>C2_ 1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140407751472960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">Zevra Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Mar. 26,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-36913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">20-5894398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">1180 Celebration Boulevard, Suite 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Celebration<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">34747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">939-3416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZVRA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001434647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MB6$0=IMK7N=@_VGW\K@:QW'1+($%JKD75^C.:KL]WEX8F9=;TKDTN,$M3U?
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " ".HWI8!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M (ZC>EAI<-^4[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( (ZC>EB97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ CJ-Z6#,K
MD/I)!   L!   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( (ZC>EB?H!OPL0(  .(,   -
M  "  8T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ CJ-Z6)>*NQS
M$P(   L              ( !:0\  %]R96QS+RYR96QS4$L! A0#%     @
MCJ-Z6#JJHN=  0  / (   \              ( !4A   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( (ZC>E@D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (ZC
M>EAED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zvra20240326_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zvra.com/20240326/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>zvra-20240326.xsd</File>
    <File>zvra-20240326_def.xml</File>
    <File>zvra-20240326_lab.xml</File>
    <File>zvra-20240326_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="zvra20240326_8k.htm">zvra20240326_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zvra20240326_8k.htm": {
   "nsprefix": "zvra",
   "nsuri": "http://www.zvra.com/20240326",
   "dts": {
    "schema": {
     "local": [
      "zvra-20240326.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "zvra-20240326_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "zvra-20240326_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zvra-20240326_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zvra20240326_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.zvra.com/20240326/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zvra20240326_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zvra20240326_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zvra.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-24-009476-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-009476-xbrl.zip
M4$L#!!0    ( (ZC>E@4# M^@10  %97   -    97A?-C0U,S,P+FAT;>U<
MZ5/<2++_//XKZC'Q9B%>=YO+^( AMLUA$^.#!>:(_?*B6JINE9%4FBJ)IN>O
M?[_,*AW=-!C/^NUXC3=V#$AU9&;EG5G:2\HLW=]+E(SW'WVW5^HR5?OJ^G]W
MMI]L;:T/\';OL7^(M__5[XM7*E=6EBH6HYFX2*H\5O;09$J<&EO*5/3%UN/-
MG<>;ZYO;XMF+S:T7VYOB]*WH]_?W,E5*$272.E7^N%*5X_ZSE? TEYGZ<65L
M;";+?JQ*%97:Y"LB,GFI<HPN5:J*Q.3JQ]RL[#_:>^PAWAN9>"9<.4MY>E[V
MG?Y#O1 ;ZT6Y*_C!6&8ZG;T0/_Q>F7+W0F?*B7=J*LY,)G/_<%<4,HYU/GDA
MUG4NU@<;.M\5466=L2^$K$JS2WL6]4:9M!.=8W!Q+7BC4EV7?9GJ"1Y:/4GJ
MO?\4,* )C9W#JI[WMX4I?^L)?M(33ED]OK$MUAKM'UTG>J1+\?SY8&/O\6A_
M[S&-PH]B_]%]L4K5^ M"ZH=\Y(K=6_"X_ZEWU]ULT+F25LN\?"%<)M.T'\G"
M[8J6.$N/NP6)88GU50U-=VP$5E:6:*&SB9 I^+K045E9M37X4$Q6A+/1PB-@
MA\5NQ6\!L=T6(T9H#I^<I"O=[0 4X FX 351__>LN('3<OH>8*61U3TQQ"8I
M3DSFKK_DV+9ODC? (Y90J$ON!9C S_]45U9"]T /%:HJ=>3$,,]-E4>@Q84I
M^F]TKL2AA%X96Y.),H%V2J138E,<I#K7$?34!<$KS%AXB?C"4/SI=&/]Z5.L
M9L5)K$TART1'XO6L4-!)6:XE0?WQX[F#/=:_*/98(GU_DG:ZIEVL,I.[DFR5
M$U$X]G0F,B5SJ/IQE8H1;-E8EX[I?*EFXN2U<+.L*$WF]A[KS\,6GPVU+Y3<
M)' I"5Q, E=8<Z5CQ=34N3?HL.1,89+#6#DL37(G@TQN 9,JGOT[Z-U5XG\%
M/3]4KM3CV2(@D/<#N#<CRZ3JB>-4#E@M_?#]L\V-C5V\%V^EC1*QN=,3Y%G1
M2['ZZLW[ET?BW=&OY[^>G!VMB3#<XW532?;$21X-_-O5=]+%\O=7YR_$/W\Y
M&ZZ)51[?$^&8#DQ6R'RVAE.RTN+8M%-T6&57Z49^4$^4)I8S(8,.CO%WER58
M!Y.4%:F,U,CTR:FS)DU5W!.QJ4:IZH\P/&Z4="VMHF0EO?KNX&+]R<[.LZ=/
MMM>$NI)I!4KE$X;4R;$J:7/:-@5T(YUJ/ "'!46PB@.+U37\S&26%HG*-<!2
MC.KYX6]K8%.X?Z4&KSLQU64B=*MQDU;CBM63UVL#4%0[XG(S[N/_0"521>E9
M6$REP[F7HC!399D.72V$0=@&'$"8D13H,7[%_' F=%B>8A-)=,8")#5.70$K
MS%#8+);6XZJNB]1@58._51X71@/\'G")TBJN:7-43.&4)^(\5:K >3@GSK&Y
M$JM'Y^=KO5M,BSBG'8F&8?#):XSF77DAL)&R)<;]HET%P(:Y3,VD'GQ^\LL0
MHZ<Z38,"Z-C?(.M!"PP>J+R3G&ZN>PEEF7VZZQK>]RS?8?+ Q6 MB9=*EADX
MU7L&K[OL%=]BY#2$-"H]T^21J:R<T+*F*B&_,(U0SB,#)FF$KB-1:DPL&LUZ
M#/+&+K,P=CI(+!C90)BL.+3R$M)TFAQ"<PV'YV][XO E_7MJP8VZP(HG^94"
M)2;$KB28++?$"#7G!XH<5K9F75.HO)_*D4JA(DCQZ-*K1P$^U0::HY%9ET#<
M8F'-".0F=&&"5,:O(-JM2?>2!+[NBHFZAM/H]!5)WJR$NR1<*RQE(DM!HHP#
MA'SA/^P3MT#.*2]2';&54^#K01R(8<G#()]S6'=@MZ"RR<!4,6""NJ QX<#;
MLYY84Q4(%YR9/^]%5,.JPJH"8H\!)Z\]?5VA(E(VS:$/Q*]*I,9<$A]-I655
M55CE,+U&;JPAUUC+52F6#_ SE_I%:U:5'LFJP,HT]_S-T=$I6RFR"*0@,J5H
MU4%@HH<M];^J(/*6K*G,+TE&P\DW;('#[ 8M"_8P^%+:8@(4,<D82P9FR?@*
M%J4^0MW('5[S],!2O<!DO:!'6OF6.D:\H%/Q-CJ6-I4Y1/L@T6HLCJY5!+L/
M27E/6D&Q)+,.6Y!BL!;$5D/8:E8&&B"\-0"K,)3/(2R ,U25NM)D&AG:#* !
MWU$%<\TNXH)+?E^Y[?G?,=K;*=)D<*XT>:&3'O\)/9C&C;,JX=^,QY!S@HP$
MIY4]4S3N:W,ZG/,"?USY)%A469H)K2NOI(;.2FL_20=)F_)N+,"IOE3^N''T
MD$>B?G]LHLIAL5J <8J&U&Z0?#IEH.(8<E<5+-W61RV9O/2GK=TBFQ0&! (P
MY+/4S$++))I( ]6C'4V%Q@+XI.X\7VD7C'1G-]["&Z:</#<F#9WJ2.&D(EM%
M-5^2G^>JB [G@<L[>7,X LTBTWC$R_1I8_4#M>_IUX+\,/.NLIX-68%8G<F.
M1SAO;-G!#&=+O!C."0H(O(M_QYI\<F]^1Q\H!7NE&%(O)\0$]PGK&A''JH6^
M,I05KAT)CZB709JW0([6QVTF-,ZM-\0U0X*FF -^)XEE-FY<S++.['@Z/50O
M,W )Q23D(>6D=4;012I-^YZC2-/!>N.@O(\%9:Q25_N>[)+PJ80SFX\M$CU)
M8%S\3!![:W-=9!-H8Z#8P[E.X%6DI%7P#F-H&AY"4>=BE8(FCC2GL"-^RIKG
MSLQ@23@2\')("Y*:!3RJ.7Z=^QBE)RC_+Z-$$2]=:T5>72ZA1:5GKEA%EB)6
M8%@4<#]*J,'#BE6O9A6N?\=?12)!S\A AV),1(P.(: UE^Q-L)%KK5.F3.U-
M$N\76-]3!%:1P[64(C1#PEF3=9J0JJ20.82&['63T8O9!!+4*4QD']XZ46LA
M7B78XBH",*V]8:-AQN/@*-?"V+%>8YB7!RD HO\\)*KZ&UX=F^(N!>S5HF=Q
M]>(OI%C)_L/(P >R/ZZLKX@( AO*4\W?#B%=_7< <:KC,J'ZR/I_+Y1E/@7>
ME?U'WSWZ[KN]TO[+J--2M%*\ .'VS<+1IRU;DZN,%W>X(G\/#E#-&+"ZNZ(F
MS+-_<5O>Z]_%$=\_WWGZW+,$;7M?7/\CT%LJNXV]\FKNKFQ&'?.2$KXS?%\]
M.J0L%V5.G,.#X*[#\YXHGY4<0?A9*P1+][&$F4\(D.-U(Q_ VMS'S5>J/U7J
MLIO#6$Q?! <([OTD05#.$S?]K+N3"JSD>:]YH^H&B\R"GY:D&3])I=RJSVY4
M7^]3)6IK0I]7?['Z^H0*5JNOEFN;[?5/4QDD10&29Q\1B\] MT^6<@+O"Q#5
MTSH2EG$&(74E)ZN# (=T7%-;@V@M%;G:6T& OS3AW/N$;#-)TTN.\(_QSBTL
M]_*8AMS(Q=V:8O0>Y,T)'TGW?1/ ;P+X^5V!BTZ4W'0S4!B1*@K1YA,(GU)]
M71:FWQ)"WRR1U5'%7\_N7U"$T=9-J=29.PKRK$*<Z:C\0IJ$2H;UB:T>O3_=
M7*N3XYZL=$8_#\X'4&/!1SBTU40,@YH-+@26=>0I3"I$AAQ*=]/%6XMYP+^^
MV$;M4%$*)^S'E=-7+W]:'K/X^7UJ- O&)SSA#BM^1$UX<VL=7YPUBRUK7.AL
ML# W&?>MF=Y\2,I1G+YZ]_/;%@=NP)K_\6@O:2*DT^&KH_[+LZ/A3_WA\<71
MV0LATZF<N=V@A(E$N9H#9E<DRF.U65SO0IQ3:C3\?IW_AWDRNJ34+QAF_M4-
M KP^7$X WZ[W)]&_>'_P1N>7=Q+@[K:T3V[IN\/M(%2^6)G?&^T/1[4#'Y1E
M+>#<8?;9NLO^P_(O01_>4L&:<C6[ZT_UEG:'M.71?NMO]=A=ZU-E!J^@.WLB
M@WG4?2_U(97#H5J;REQ(J3?IY=;&W98]\_0,):Y3:4NQ43N$'AD [,@'CKU=
M71K_+=:PF2PA<IPF.DHZ]I5RC0$YGRB$]J"EQU0MHH5<M[GEV7I/;.S@G\WM
M=>YI\8G8QXB'UP9=J#?GH584OU*Z7XIR:CS +;E["X?3]78)]MX\\+1"F6@;
MN_E-FOHD(48'J_/*XV15I+@PPJ6I%ETF%!;U-30,HTB;^Q5RY;>HI\8UQPP8
MOV8;IA_T&5BSJ:I/#6=RX>E :\%!H@)@@DC?=5MOQMIR\IE>M)M(06%V&M+4
M'CYB> 0XX!@J=<:4=VA+&KZ&<6.=1*8ABFC7<32$ZH9CXEM0]U(QK@M+\=0"
M,8;U.7S><.!KKZ$@APUV=A".00YN>&KDO6UN!YO8U);A9K0M!\LS%<RDW0H2
M _9DW3\C!)JMVK-MUIR+EGBM!YF(KBN!BY4Y4H'WJO-U6323'[@C[-8J6;-L
M"+EQV'?GM+ I.?XN B_7.PT1*X:.@<Y631TN),GCCT3O]/;>$7P(N44.A\'Q
M"VH/X*R=IU)H ?!%Z7I#T*BIZ]_-7 _.'[FEM8]Z&!^P2W)R>V>GT*YN=O7=
M([%V[+[SC24907>R@1K-[I%T;@WO@BI6UY0L4GG4SDUE02:=]2:OPU8<\:*V
M5E%/%C=Q0#*\X?3 L7=#",#Q<&S;_!8R1KQ)U4+J5X%A,% "L<@IUF@!'70D
MG(JU7I?7("82B(&4,+V*^V)T!*M"S:V7[&L9ZFV9:LRXS*FL3/7E;KM-S\NG
M6FRY,3!R^)-*H])/J&#L. ?A 6&T*:LO"X .A<F-09K;U:#\7$<+L&<65DR5
M9,*,*TN0]3PU,K+-L6)EZAL$L";HF'%[2N*;)S+JGO7T[W51K;/[-(U[<^J:
MLC\.\V [5T]*$A/J*<O(J^YQ-C>F_ -"2 W:4OMR*)/P*5[S0)SMUM,>XM<;
M'6X_YYH<Y_.2;VF0\+75[5C+26YH_<":/;HRE5#)Q+N8;+GJGJG"%%7J'9=,
MSJC3(:-S3@$_9#CVI7]'%Q5;_R@QGMNI9WNF2M_-U&S;\R_Y8:9=YSDQJO73
M6G I)>/[I$+\\%4RR;V,CW=<'K"=N?/F07OQP(GY'G"O]E1)_A;502GW1^TS
M_<455N/^V]/7ON[!'7?P'(7DAJVZIX7O:$CJP9]8%;.(K Y/3QK3U&G-9 Z?
M(/@C47QOL4#N\XZ'G#GT0N4[S/SDCZ8HPR63X\/AVFUQ=1,P=9;DE8XH;QWY
M"N]P E,Y"ZL='F$U@I?357JL27$<_N8]3:8 \"/%4O>V<I+A/$H4PB)XJK^(
M-K4 (S!R)2=/&Q6F*#*D)ZZ:3$C'43/SX6^\I10IW>GHM*\26G)4<;2ZT-C#
MA].;V_MDZ=Y?I8;X\S[KS2M+#UB%++GDVGJH]76L< .+?HZ\N^(B]BY[P1*3
MC-46DCQ(KDE09QRY5I!XU]2(*#=7-RTS<X<]@N^:ZHPM-5[DYD9_-#RT]Y4E
M*^FX$9VW&7&"*-5CU>=H-'0.MOC0G0-E"LA'JJ^:&D@706J?IF>^7<\CU8^M
M)@\OIK8Z4S 4OJ4[RY2E1F3]AU=9_I[$1)-WU[G41N!1DUZXK^!K:=>"M6UW
M40 -<84#S9!F\E)Q>-I2J=/N[5,>BV>3 >YR]DW*":QC:E8WW,+9\!PE?9E6
M5]KIT@,^G4X'?_"M A#0/\+,,32GF8J*KBOYA[\%JT"+*0O_ZP+<@R"-C:)_
M1T4,%9]\*WU]*WU]*WW]?YCM UFQHCV@AF[+]N?8WR?KOS&&HR&.[/B&V@.V
MY>'.,*6'K/(:CV)4<@E]BL33+ TT<PW-V"*&4#DT03:-R[""9,7/%4)079(]
M>J/KNU[B3/'-VV'$WO;&\^=/!LW1+-DFI'3Y*D#G,<?QL>% %X#S'6;XV5"V
M,'@)W0"U'&- 08<X6(P1A<Q=U"(,R+EC!Z*VR\T._IY ?:< ,4]&B27V6AI/
M.UQ@!1Y4  ,9FV(B[;O0ZP '8;?3ZM)KKHB0M:$B4RBO=-K V8&:6\;1RG!Q
M8@ .7499*HM]/?B^Q-7L-G>1]JX[M+L+P9Z_I=DE >?L^ ZFI]/</EV:2BI3
MY7QA+2+%4D=8'CV^.V[&N_<B*2'?4#9<,##-[R+"/ XYO4](HYO+I+6CHS$D
M"A!S!H]&Q<;)B5K$^9/;8@(2#>"IK/(HX8._X>ZUV"R!OL4I)/,(X]I!C#QY
MPJRN#]C>@UKD:>(@4*+T);G@2TK.1G*:M(6/+E>%"W[+G/<[!9/&-P%JMZ-K
MZ:5#$T*H.BU0"Z4G.TA Z><HL#$G56>\ P+2#P&5^FL#(;>+A:K<_TZ?=K"D
MKTIVJ*UVES4IB>.(I^@+8$$'&!O4!RLZNIC#%,>;JKU5W*,4-N/$(0MQ3Y30
MQ=&@?OC"$B40K2=C<TO3=\+1:8\K^E;2/1<$^M;W@1N&-]7MU;G;E7"=?;X+
M53Y7Y2*K1_[>5*RHO%ZG.</-V#/03!S[*<V-6_^IL^8R;2,K0W]Y^HS5!!W_
M,6GTC?7^3TU*9::D)?G!EH<J4MD(L&UM\"="-CG]415Q?9%K?O%_5)+ND(*F
M-]?_1[/^[WY4V.)<%6788YWWV/+'/[^RI]!80Q-.7-O5UC%3-.?H.A0H$9.%
MJ!&A'I?]I]XXPDYZCO0X^*S]'982K.:SNUP&#73WW-'CB@T\%^E8\>AP8S*5
MTQYM!X'D]+57'Z.T-J*4RJ&<<2@IZ#%G;DASY65],ZQE[2NMICZ\9LP&8E@G
MJZ?MA6CN*.X((> 9$Z+^C#Z*(W.Z=(C61W1+#0M']-45PHROFK'$\2ISF_#'
M./C>!)0.5$)4UCQ]QV8NX5O+M/J(MF5AJ0J3>S)VOA;08B\;@\IGYOL:?--#
M&5H)%CVAKS(Z_HC?[+7T ;E_4?FU^L5WT>"=CA*3BO=1XG)E]T9V_]'_;(C5
MIUNP_$^?;/<WGVP_X:>Y\4/^WJ0$'AJIP"YGE7.&FYSX*P"!;[[:@.HN:@QC
MZ#LI7I%V5=>2/L1 GYX9' X:)MK9WED3S[<W^T]VUK?XJ>1) UG/^+LE@M:?
M0TC3Z"'RU<DDEY$VXE6E8!&LZ9\9=Q<IM_FI]K,&DWJ6->Z3R?F9;P!TTCAO
MAN<7_38IM31I]EF3874N"+_0EV@AC_P]W?\#4$L#!!0    ( (ZC>ECDGVQ[
M:@,  &\-   1    >G9R82TR,#(T,#,R-BYX<V3-5TMOXS80OA?H?V!UIRG9
MW6UMQ%D$3;LPD&V+31;H;4%+8YNH1*HDE<?^^LY0#UN)G,@^%#V9XGS?O#B<
MH2\^/!8YNP?KE-'+*)G$$0.=FDSI[3+Z<LNO;G]9K2+FO-29S(V&9:1-].'R
M^^\N?N#\(VBPTD/&UD_L;E?I#.RU*8#]::R7.>-L)J8_B6D\_9$ET\7TYT4R
M8U>?."?^H\L6+MU!(1DZH=WB<6USM8QVWI<+(1X>'B:T,S%VBQKBF5":W$@A
M:O$NZZ$?9BTV$7]]NKD-NCMPKO3?0_!D/I^+(&VASI>V0P87'*23K;D7)*%H
M9BWTA=*^QR1>2]=YG'G+_5,);IB#8D%B,A'S..'3)#K(3>;[7C5FWHE:V!D!
M->P]"GK.IZ;2WCX-@QMAC^!4>B0O*NUKKJS%,CJFNI'V*/"8[H;A).E!O]U;
MV4L@;4Q24X1"BV?3]Q&3WENUKCS\9FQQ#1M9Y9B]2O]3R5QM%&18YSD4H'T/
M<"#VTF[!_RX+<*5,X0V#;4&KHL329WJ0=JR<ZUMP8U+IPS4\2J$OWO(X;?%D
MRF?)!$U'XF0?YL*:'(2&+=WA<7[DUO98Y,6<O$C>C_3BV(T:LNZ.XL.*T^J<
MX =OVC$'WF*&;W=*]"]N[L@*: F4]'?GI'O? D9ENX73XI1<O]))1MD]I+0?
M9]O?-Z=Q%=; :7%^S/T6-R[H0T[W=;8+!VUSE/D.'U9]LXUAJ;7Q04?KBBQ+
MI3>&/FG6+=J!]QDV+,S4A;0IM8O7)Z\HK2G!>@7N<&8&!3L+FV5$'9>WW?9K
M+M<3G 4MY(6!?M<,[0HID-_LW6NY='>7D<.<YE"G^+\,)(/-J8$@16E%A_"_
MBZ:T<&HT2'$XA.5I\1#U#D5,X0L0IZ$/DYQG)JW" A^K''^5?^)4GK8(^B-&
MO"^?5Z_/\MJQ\5H[K_8G4S]4QCP,+^,XQF?R=6/C<'FE,_9K,,=6>W,7XIFM
MSGSE(/M#7X9U*O.TRKNL-J0&,43H5]7;^.?G]H(A>@<5=IXU##'<4IIG&9-K
MYZU,\5'F;85E1T=-9_6U31#FIT[/ZO"(J2LNHS<P*L=V0,59JW85VE*^(NE'
M:ZIR&87_(@N%)8 OP5"$]0[ZA'^-5KA/86&9AEV\),ID=P&75;8V([H@Z_Z+
MG_\"4$L#!!0    ( (ZC>EC$/JE.V@0  .8L   5    >G9R82TR,#(T,#,R
M-E]D968N>&ULS5I=C]HX%'U?:?]#-OL<PD>G[:#2"C'3"G6F@P:JK?JR,LD%
MK#HV<IP!]M>O'3Z&*;%C&(SR B$^N3[G^NOFB ^?E@GQGH"GF-&.WZC5?0]H
MQ&),IQW_^S#H#GO]ON^E M$8$4:AXU/F?_KXYQ\?_@J"+T"!(P&Q-UYYHUE&
M8^ W+ %OP+A Q N\5MA\%S;KS3=>H]ENOF\W6E[W/@C4\P337VWU,48I>)('
M3?.?'7\FQ+P=AHO%HK8<<U)C?"ICU%OA%NUOX*HU%KL']L%7X;IQ!ST(O6CE
MV,;U]768M^Z@*2X"RJ"-\,?]W3":08("3%52(L4EQ>TTOWG'(B3R3)9*\+0(
M]2O8P@)U*V@T@U:CMDQC?Y<XQ"/."#S"Q-M<?G_L'V8"4Q'&. DWF! 1(@GG
M$68<)EJBV_2I_J]4SW_O/2E6<SD/4IS,"?CA:RG%+$&8!@DD8^ GDBN,<6::
M. &JEDFP[NQ4IIHPYR4[D]%XE(TAV/5W(E]#)&?YA0G*B'A]@E_&T=#=<OV=
MJ.KIOR>.:A%+\AVLWFJ^#7.J<N$+D+T(.891EE_([3&0WUBLY,8P83S)]X&7
M$E2T8!LIYWIT((T&J113K(!W\N<&JZ@Z4;,F 4L!<K_?VY((BPZ&+-T.>0I1
M;<J>PABPZK^E+E0R6NM! _SO;=[AS8M50= 82,?7-:^9$+7K,KZ7C\LQ*9YD
M9V=TLQF9_O-HC-"80 &[,NCE&,JY"'TYM5([E@=P1TSO8(K(>@R[2UQ$3H-P
MG+F1#&_(U'ZS8R8#X)C%MS2^D3N#@5(ASNF:?(0I3@5'5'Q#21$U$\PIL[ZL
MFOF<\7PJ#]66VF,9%7S58[&>J-533GE_Q@2^9?METP')0XA31B.T[,?J])G@
M=35=0J\$[Y1K-XXYI.GF2^U@#2U/ _82''OR\H&/V$)_I&F1E^"7S_X'/N#L
M":]?JXPD-?!+,!TP63*1GWAN7-HFL".6:N"Z')"&5U&SJS-6!B2#&:/ZO44'
M<<3H'XZ%+%A[+$DRNMDHBLY^(\X1MR$C.)+E.YW>RTG-,2(%Q/0@1ZP&'%06
M0*ZNO/Y0U3Y_F$P*1[,<?!F6_33-@!_%5?N(J]&&*).3;-5HCD=8%-;P.H@C
M1B..E.$W7"5C5C3U"ML=9^=V&<T0G8*FSC/!G)X!MPGPJ4S&%\X68B;GT1S1
ME?80,*(=\>S*21VKB?V9H&D!L\)VISGKR<XX(GVYPI9?09\M#4['[=GUZ/+(
M8URNWXY?ET_ECE [(BR%N.,+GNVFQL9L.MWMFW"6F%\269E=(;LH$]$XNXB7
M+L5)*HJMCJV:2PR*P8M\5E3J?S"+E_QG5:?IVMQD5,!2W)+\G.GX*4S5Q=&Z
M]ZQWH\Y#!X4=XPE=<&(6V?6ODW9HCUC(:596CL%:L=#5JIRN<E_&0M:;BLHZ
MPL6Q4'E5494Z&\A"TMN*2K*RCBSTO:NHOE++R4+;^VIKTYE5%LJNJZW,Z'#9
MG-7G*H4=Z3,X8S;JJE>*Z/TU&SW5JT7,#IV-INK5(1;VGHVPZE4B9?:@C:KJ
M51ZVMJ*-NNH5(<<9D38:JU>(F*U,&TW5*T ,?JB-H.K5'>5NJLW+=%7K#0L3
MUD9>]0H.@Y-K(ZAZ%8>%#;SG-X:_:9-A?WW<W5<?ZA^T\L[_4$L#!!0    (
M (ZC>E@2F1ZA^ 4  $0\   5    >G9R82TR,#(T,#,R-E]L86(N>&ULS5MM
M;^HV%/X^:?_!8U\VJ6D*W5NKME>H[;U"ZYL*U:9=35-(#%A+?)!C6OCWLQW>
M G9( #O[4@(Y>9Z3YSSQL9/TZM,TB=$[9BD!>MUHGIXU$*8A1(0.KQMO7:_=
MO>UT&BCE 8V"&"B^;E!H?+KY]INK[SSO"Z:8!1Q'J#]#O=&$1IC=08+1"S >
MQ,A#YW[K5[]UUOH)-5N7K=\NF^>H_>AY\OB8T'\OY9]^D&(D\J"I^GK=&'$^
MOO3]CX^/TVF?Q:? A@+C[-Q?1#?FX7)OQ)<'K ?_[&<[EZ%;T!_G*K9Y<7'A
MJ[W+T)3H @5HT__S\:$;CG 2>(1*44*92THN4_7C X0!5TKN/ 5DC)#?O$68
M)W_RFBWOO'DZ3:/&4C@&,7[% R0_WUX[1L8+7T;X% ]EG1Z"/HY%Q@IBQ/!
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M^X/@F)1+H_OX-X_UXI\ P4K(8T+#0)S ,ET^CF9VN1IY%&8%$<AV "Q^?XP
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M @H*S36=*1IB ][E :G7"V54(-K<:IJ[\:(K0)!@HIHMT#ZF8"M"!*P8,,;
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MP-C/&QI"I@#]@0K#!?T%)O>8>2#-Q]0+J>48W >[2SP^9((_#L"7P0O(]).
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M],[^'U!+ 0(4 Q0    ( (ZC>E@4# M^@10  %97   -              "
M 0    !E>%\V-#4S,S N:'1M4$L! A0#%     @ CJ-Z6.2?;'MJ P  ;PT
M !$              ( !K!0  'IV<F$M,C R-# S,C8N>'-D4$L! A0#%
M  @ CJ-Z6,0^J4[:!   YBP  !4              ( !11@  'IV<F$M,C R
M-# S,C9?9&5F+GAM;%!+ 0(4 Q0    ( (ZC>E@2F1ZA^ 4  $0\   5
M          "  5(=  !Z=G)A+3(P,C0P,S(V7VQA8BYX;6Q02P$"% ,4
M" ".HWI8<-DOOG8$  !^+0  %0              @ %](P  >G9R82TR,#(T
M,#,R-E]P<F4N>&UL4$L! A0#%     @ CJ-Z6+#V[/8^&0  6:8  !,
M         ( !)B@  'IV<F$R,#(T,#,R-E\X:RYH=&U02P4&      8 !@"$
) 0  E4$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>zvra20240326_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zvra-20240326.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434647</identifier>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-377">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-378">0001434647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-37">2024-03-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-43">Zevra Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-56">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-60">001-36913</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-64">20-5894398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-88">1180 Celebration Boulevard, Suite 103</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-98">Celebration</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-104">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-113">34747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-130">321</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-132">939-3416</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-388">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-389">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-390">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-391">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-392">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-393">ZVRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-394">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-395">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
